Fred Saad

107.6k total citations · 17 hit papers
1.2k papers, 36.7k citations indexed

About

Fred Saad is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Fred Saad has authored 1.2k papers receiving a total of 36.7k indexed citations (citations by other indexed papers that have themselves been cited), including 937 papers in Pulmonary and Respiratory Medicine, 494 papers in Oncology and 324 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Fred Saad's work include Prostate Cancer Treatment and Research (786 papers), Prostate Cancer Diagnosis and Treatment (317 papers) and Radiopharmaceutical Chemistry and Applications (304 papers). Fred Saad is often cited by papers focused on Prostate Cancer Treatment and Research (786 papers), Prostate Cancer Diagnosis and Treatment (317 papers) and Radiopharmaceutical Chemistry and Applications (304 papers). Fred Saad collaborates with scholars based in Canada, United States and Germany. Fred Saad's co-authors include Karim Fizazi, Neal D. Shore, Johann S. de Bono, Cora N. Sternberg, Kim N., Allan Lipton, Paul N. Mainwaring, Anne‐Marie Mes‐Masson, Pierre I. Karakiewicz and Howard I. Scher and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and Journal of Clinical Oncology.

In The Last Decade

Fred Saad

1.2k papers receiving 36.1k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy

2012 3.3k citations Howard I. Scher, Karim Fizazi et al. profile →
Olaparib for Metastatic Castration-Resistant Prostate Cancer

2020 1.4k citations Johann S. de Bono, Karim Fizazi et al. profile →
A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate Carcinoma

2002 1.2k citations Fred Saad et al. profile →
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study

2012 1.0k citations Karim Fizazi, Howard I. Scher et al. profile →
Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer

2018 868 citations Matthew R. Smith, Fred Saad et al. profile →
Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer

2009 786 citations Matthew Smith, Fred Saad et al. profile →
Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer

2018 677 citations Karim Fizazi, Fred Saad et al. profile →
Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases

2011 571 citations Fred Saad, Janet E. Brown et al. profile →
Pathologic fractures correlate with reduced survival in patients with malignant bone disease

2007 492 citations Fred Saad, Allan Lipton et al. Cancer profile →
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer

2020 474 citations Karim Fizazi, Fred Saad et al. profile →
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials

2012 420 citations Allan Lipton, Karim Fizazi et al. profile →
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial

2018 281 citations Fred Saad et al. profile →
Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer

2020 266 citations Karim Fizazi, Fred Saad et al. profile →
Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer

2020 259 citations Neal D. Shore, Fred Saad et al. profile →
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

2021 183 citations Johann S. de Bono, Celestia S. Higano et al. profile →
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial

2023 132 citations Fred Saad, Neal D. Shore et al. profile →
Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

2023 99 citations Bertrand Tombal, Fred Saad et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Fred Saad

Since Specialization

Citations

This map shows the geographic impact of Fred Saad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fred Saad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fred Saad more than expected).

Fields of papers citing papers by Fred Saad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fred Saad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fred Saad. The network helps show where Fred Saad may publish in the future.

Co-authorship network of co-authors of Fred Saad

This figure shows the co-authorship network connecting the top 25 collaborators of Fred Saad. A scholar is included among the top collaborators of Fred Saad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fred Saad. Fred Saad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effects of Enzalutamide on the Sexual Activity of Patients with Biochemically Recurrent Prostate Cancer: A Post Hoc Analysis of Patient-reported Outcomes in the EMBARK Study 2025 ·European Urology ·Stephen J. Freedland, John P. Mulhall, Martin Gleave, Ugo De Giorgi, Fred Saad, Antti Rannikko, Jasmina Ivanova, (unknown), Arlene Reisman, Arijit Ganguli, (unknown), James Turnbull, Neal D. Shore	4
2	Critical care therapy and in-hospital mortality after radical nephroureterectomy for nonmetastatic upper urinary tract carcinoma 2024 ·Urologic Oncology Seminars and Original Investigations ·Francesco Di Bello, Carolin Siech, Mario de Angelis, Natali Rodriguez Peñaranda, Zhe Tian, Jordan A. Goyal, Claudia Collà Ruvolo, Gianluigi Califano, Massimiliano Creta, Fred Saad, Shahrokh F. Shariat, (unknown), Felix K.‐H. Chun, Stefano Puliatti, Nicola Longo, Pierre I. Karakiewicz	8
3	The effect of race/ethnicity on cancer-specific mortality after trimodal therapy 2024 ·Journal of Racial and Ethnic Health Disparities ·Mario de Angelis, Andrea Baudo, Carolin Siech, Letizia Maria Ippolita Jannello, Francesco Di Bello, Jordan A. Goyal, Zhe Tian, Nicola Longo, Ottavio De Cobelli, Felix K.‐H. Chun, Fred Saad, Shahrokh F. Shariat, Luca Carmignani, Giorgio Gandaglia, Marco Moschini, Francesco Montorsi, Alberto Briganti, Pierre I. Karakiewicz	5
4	Safety and effectiveness of the radium‐223–taxane treatment sequence in patients with metastatic castration‐resistant prostate cancer in a global observational study (REASSURE) 2024 ·Cancer ·Celestia S. Higano, Sabina Dizdarevic, John Logue, (unknown), Saby George, Igle J. de Jong, Jeffrey Tomaszewski, Fred Saad, Kurt Miller, (unknown), Per Sandström, Frank Verholen, Bertrand Tombal, Oliver Sartor	4
5	Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States 2023 ·Annals of Epidemiology ·Cristina Cano Garcia, (unknown), Mattia Luca Piccinelli, Stefano Tappero, Andrea Panunzio, Francesco Barletta, Reha‐Baris Incesu, Zhe Tian, Fred Saad, Anil Kapoor, Alberto Briganti, Carlo Terrone, Shahrokh F. Shariat, Derya Tilki, Alessandro Antonelli, Ottavio De Cobelli, Luis A. Kluth, Andreas Becker, Felix K.‐H. Chun, Pierre I. Karakiewicz	4
6	Conditional survival for non-metastatic muscle-invasive adenocarcinoma of the urinary bladder after radical cystectomy 2023 ·Surgical Oncology ·Stefano Tappero, Cristina Cano Garcia, Reha‐Baris Incesu, Mattia Luca Piccinelli, Francesco Barletta, Simone Morra, (unknown), Zhe Tian, Fred Saad, Shahrokh F. Shariat, Marco Borghesi, Carlo Terrone, Pierre I. Karakiewicz	3
7	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study 2020 ·Clinical Cancer Research ·Edwin M. Posadas, Kim N., Ronald de Wit, Maja J.A. de Jonge, Gerhardt Attard, Terence W. Friedlander, Margaret K. Yu, Peter Hellemans, Caly Chien, (unknown), (unknown), Fred Saad	12
8	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer 2019 ·Journal of Clinical Oncology ·James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, (unknown), Philip W. Kantoff	183
9	Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer 2019 ·Clinical Cancer Research ·Wolfgang P. Fendler, Manuel Weber, Amir Iravani, Michael S. Hofman, Jérémie Calais, Johannes Czernin, Harun Ilhan, Fred Saad, Eric J. Small, Matthew R. Smith, (unknown), Thomas A. Hope, Isabel Rauscher, Anil Londhe, Angela Lopez‐Gitlitz, Shinta Cheng, Tobias Maurer, Ken Herrmann, Matthias Eiber, Boris Hadaschik	183
10	Expression of AR-V7 and ARv567es in Circulating Tumor Cells Correlates with Outcomes to Taxane Therapy in Men with Metastatic Prostate Cancer Treated in TAXYNERGY 2018 ·Clinical Cancer Research ·Scott T. Tagawa, Emmanuel S. Antonarakis, Ada Gjyrezi, Giuseppe Galletti, (unknown), Daniel Worroll, John A. Stewart, Atef Zaher, Ted P. Szatrowski, Karla V. Ballman, Katsuhiro Kita, Shinsuke Tasaki, Yang Bai, Luigi Portella, Brian J. Kirby, Fred Saad, Mario A. Eisenberger, David M. Nanus, Paraskevi Giannakakou	86
11	Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive Agents 2016 ·Clinical Cancer Research ·Allan Lipton, Matthew Smith, Karim Fizazi, Alison Stopeck, David H. Henry, Janet E. Brown, Neal D. Shore, Fred Saad, Andrew Spencer, Li Zhu, Douglas Warner	32
12	The Added Value of Circulating Tumor Cell Enumeration to Standard Markers in Assessing Prognosis in a Metastatic Castration-Resistant Prostate Cancer Population 2016 ·Clinical Cancer Research ·Glenn Heller, Karim Fizazi, Robert G. McCormack, Arturo Molina, David B. MacLean, Iain J. Webb, Fred Saad, Johann S. de Bono, Howard I. Scher	43
13	Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate–Treated Castration-Resistant Prostate Cancer Patients 2015 ·Clinical Cancer Research ·(unknown), Charles J. Ryan, Kim Stuyckens, Matthew R. Smith, Fred Saad, Thomas W. Griffin, Youn C. Park, Margaret K. Yu, An Vermeulen, Italo Poggesi, Partha Nandy	50
14	CD73 Expression Is an Independent Prognostic Factor in Prostate Cancer 2015 ·Clinical Cancer Research ·(unknown), Roxanne Charlebois, Guillaume Chouinard, Bertrand Allard, Sandra Pommey, Fred Saad, John Stagg	162
15	Systemic Therapy in Men With Metastatic Castration-Resistant Prostate Cancer: American Society of Clinical Oncology and Cancer Care Ontario Clinical Practice Guideline 2014 ·Journal of Clinical Oncology ·Ethan Basch, D.A. Loblaw, Thomas K. Oliver, Michael A. Carducci, Ronald C. Chen, James N. Frame, (unknown), Sébastien J. Hotte, Michael W. Kattan, Derek Raghavan, Fred Saad, Mary-Ellen Taplin, Cindy Walker‐Dilks, J. Koudy Williams, Eric Winquist, Charles L. Bennett, (unknown), R. Bryan Rumble, Stacie B. Dusetzina, Katherine S. Virgo	165
16	TMPRSS2-ERG Status Is Not Prognostic Following Prostate Cancer Radiotherapy: Implications for Fusion Status and DSB Repair 2013 ·Clinical Cancer Research ·Alan Dal Pra, Emilie Lalonde, Jenna Sykes, (unknown), Adrian Ishkanian, Alice Meng, (unknown), John R. Srigley, Anthony M. Joshua, György Petrovics, Theodorus van der Kwast, Andrew Evans, Michael Milosevic, Fred Saad, Colin C. Collins, Jeremy A. Squire, Wan L. Lam, Tarek A. Bismar, Paul C. Boutros, Robert G. Bristow	33
17	p53 Inhibits Angiogenesis by Inducing the Production of Arresten 2012 ·Cancer Research ·(unknown), Wissal El-Assaad, Xue Qing David Wang, (unknown), Véronique Barrès, Mathieu Latour, Anne‐Marie Mes‐Masson, Fred Saad, Yoshikazu Sado, Josée Dostie, Jose G. Teodoro	52
18	PTP1B Is an Androgen Receptor–Regulated Phosphatase That Promotes the Progression of Prostate Cancer 2012 ·Cancer Research ·Laurent Lessard, David P. Labbé, Geneviève Deblois, Louis R. Bégin, Serge Hardy, Anne‐Marie Mes‐Masson, Fred Saad, Lloyd C. Trotman, Vincent Giguère, Michel L. Tremblay	69
19	eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression 2010 ·Proceedings of the National Academy of Sciences ·Luc Furic, Liwei Rong, Ola Larsson, Ismaël Hervé Koumakpayi, Kaori Yoshida, (unknown), Emmanuel Petroulakis, Nathaniel Robichaud, Michaël Pollak, Louis Gaboury, Pier Paolo Pandolfi, Fred Saad, Nahum Sonenberg	398
20	Cancer Treatment–Induced Bone Loss in Breast and Prostate Cancer 2008 ·Journal of Clinical Oncology ·Fred Saad, Jonathan D. Adachi, Jacques P. Brown, (unknown), Karen A. Gelmon, Robert G. Josse, Kathleen I. Pritchard	134

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact